Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate the Effectiveness(Immunogeneicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* healthy Korean adults (age: over 18 years)~* who got the basic vaccination of DTP(Diphtheria, tetanus, pertussis) in the past~* Subjects willing to provide written informed consent and able to comply with the requirements for the study~Exclusion Criteria:~* subjects who have already got the additional vaccination of Td within 5 years~* subjects with antitoxin of diphtheria and tetanus ≥1.0 IU/mL (ELISA)~  * only applicable in step I~* subjects who have not recovered from the acute disease within 2 weeks~* subjects who have the medical history of allergic disease related to the components of investigational drug~* who got the treatment of blood product and immunoglobulin product within 3 months~* females who are pregnant~* females who are breastfeeding~* subjects who are infected from the diphtheria and tetanus~* subjects who have experienced the severe adverse events for the diphtheria and tetanus vaccination~* Subjects who are scheduled to participate in other clinical trial studies during the study~* Subjects who have participated in any other clinical trials within 4 weeks of the administration of the study~* Those who take the other medicine that affects this study or are vaccinated other vaccines~* Subject who have received adrenocortical hormones or immunosuppressive drug within 4weeks of enrollment~* Subjects with a history of chronic disease obstacles to the study.~* Subjects who have episode of acute febrile (at least 37.4) after injection of vaccine during the study~* Subject who have plan of operation during the study.~* Individuals with other clinically significant medical or psychological condition who are considered by the investigator to be ineligible for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- GC1107 (Type: EXPERIMENTAL): 0.5ml, intramuscular, a single dosing
- Tetanus and Diphtheria(Td vaccine) (Type: ACTIVE_COMPARATOR): 0.5ml, intramuscular, a single dosing

Based on this trial design, predict the completion outcome and termination type (if applicable).